Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Italy Fines Apple €98.6 Million Over App Store Dominance 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
NEW YORK, April 01, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq:RMTI) between September 9, 2015 and February 29, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired Rockwell securities between September 9, 2015 and February 29, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/rockwell-medical.
The complaint alleges that the Company failed to disclose that: (1) Rockwell’s main product offering for Triferic has not yet been approved by the FDA; and (2) Rockwell is seeking to obtain transitional add-on payment reimbursement for Triferic with the Centers for Medicare & Medicaid Services instead of bundled reimbursement.
If you suffered a loss in Rockwell you have until May 3, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/rockwell-medical.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
